Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Y-Mabs Therapeutics (YMAB)
NASDAQ:YMAB
Holding YMAB?
Track your performance easily
YMAB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.60 - $20.90
Previous Close$12.47
Volume180.36K
Average Volume (3M)361.67K
Market Cap
$547.22M
Enterprise Value$470.00M
Total Cash (Recent Filing)$78.64M
Total Debt (Recent Filing)$1.42M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Aug 08, 2024EPS Estimate
-$0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding43,882,638
10 Day Avg. Volume269,515
30 Day Avg. Volume361,674
Standard Deviation0.23
R-Squared0.02
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)5.22
Price to Sales (P/S)22.54
Price to Cash Flow (P/CF)-16.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.54
Enterprise Value/Gross Profit6.40
Enterprise Value/Ebitda-31.03
Forecast
1Y Price Target
$31.20Price Target Upside140.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Y-Mabs Therapeutics News
PremiumStock Analysis & Ideas
Oppenheimer Predicts Up to ~580% Jump for These 2 ‘Strong Buy’ Stocks
PremiumCompany Announcements
Y-mAbs Reports Third Quarter 2024 Financial Results
Bulls Say, Bears Say
Bulls Say
Financial PerformanceDANYELZA provides cash flows to fund continued pipeline expansion.
Market OpportunityYMAB's radioimmunotherapy platform is viewed as an attractive opportunity for big pharma interested in building out their pipeline or entering the radiopharma space.
Pipeline DevelopmentThe SADA program has substantial preclinical support and could represent a platform to generate next-generation radiopharmaceuticals with broad potential utility.
Bears Say
EarningsY-mAbs recorded a net loss of $0.15 per share compared to the previously forecast net loss of $0.11 per share.
International MarketsInternational choppiness weighs down Danyelza.
SalesDANYELZA's sales represent an 8.3% decrease compared to 3Q23.
---
Ownership Overview
29.85% Insiders
10.06% Mutual Funds
9.48% Other Institutional Investors
50.60% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
YMAB FAQ
What was Y-Mabs Therapeutics’s price range in the past 12 months?
Y-Mabs Therapeutics lowest stock price was $4.60 and its highest was $20.90 in the past 12 months.
What is Y-Mabs Therapeutics’s market cap?
Currently, no data Available
When is Y-Mabs Therapeutics’s upcoming earnings report date?
Y-Mabs Therapeutics’s upcoming earnings report date is Aug 08, 2024 which is 141 days ago.
How were Y-Mabs Therapeutics’s earnings last quarter?
Y-Mabs Therapeutics released its earnings results on May 07, 2024. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.136 by -$0.014.
Is Y-Mabs Therapeutics overvalued?
According to Wall Street analysts Y-Mabs Therapeutics’s price is currently Undervalued.
Does Y-Mabs Therapeutics pay dividends?
Y-Mabs Therapeutics does not currently pay dividends.
What is Y-Mabs Therapeutics’s EPS estimate?
Y-Mabs Therapeutics’s EPS estimate is -$0.12.
How many shares outstanding does Y-Mabs Therapeutics have?
Y-Mabs Therapeutics has 43,882,637 shares outstanding.
What happened to Y-Mabs Therapeutics’s price movement after its last earnings report?
Y-Mabs Therapeutics reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.136. Following the earnings report the stock price went down -20.918%.
Which hedge fund is a major shareholder of Y-Mabs Therapeutics?
Among the largest hedge funds holding Y-Mabs Therapeutics’s share is Caxton Associates LP. It holds Y-Mabs Therapeutics’s shares valued at 306K.
---
Y-Mabs Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.20 (140.37% Upside)
$31.20 (140.37% Upside)
Blogger Sentiment
Neutral
YMAB Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 23.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 13.0%
Last 30 Days ▼ 13.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
74.40%
12-Months-Change
Fundamentals
Return on Equity
-20.93%
Trailing 12-Months
Asset Growth
-10.28%
Trailing 12-Months
Company Description
Y-Mabs Therapeutics
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops novel antibody therapeutics for oncology targets. The company's services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.
---
YMAB Earnings Call
Q1 2024
0:00 / 0:00
---
YMAB Stock 12 Month Forecast
Average Price Target
$31.20
▲(140.37% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Crispr Therapeutics AG
―
AnaptysBio
―
Arvinas Holding Company
―
Best Analysts Covering YMAB
1 Year
1 Year Success Rate
8/12 ratings generated profit
1 Year Average Return
+66.19%
reiterated a buy rating 8 months ago
Copying William Maughan's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +66.19% per trade.
---